Imunon reports Phase 2 OVATION 2 trial: 11.1-month OS increase in advanced ovarian cancer with IMNN-001

Imunon, Inc.

Median OS improved by 11.1 months (40.5 vs 29.4) in ITT; HR 0.74 (0.42-1.30).
In patients receiving ≥3 doses, OS extended by 15.7 months (45.1 vs 29.4); HR 0.64.
PARP inhibitor subgroup: median OS not reached in IMNN-001 arm vs 37.1 months; HR 0.41.
PFS primary endpoint: 3-month improvement (14.9 vs 11.9); HR 0.79.
Company plans registrational Phase 3 study to begin in Q1 2025; End-of-Phase 2 meeting with FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.